The final five compounds that were screened out are flavonoids, which can combine with the screened‐out target genes PPARγ, PPARα and PPARδ, and thus show potential as drugs for NAFLD. This evidence concerns the gene PPARG and metabolic dysfunction-associated steatotic liver disease.